Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Qiangdu Prescription (BSQD) is a Traditional Chinese Medicine (TCM) herbal formula developed by the China-Japan Friendship Hospital, specifically within its rheumatology department, for the treatment of ankylosing spondylitis (AS). The prescription is designed based on the TCM principle of "tonifying the kidney and strengthening the Du meridian," which is believed to address the underlying pathogenesis of spinal stiffness and pain in AS patients. It typically comprises a combination of herbs such as Rehmannia glutinosa, Epimedium, and Cibotium barometz. Clinical and preclinical studies suggest that BSQD exerts therapeutic effects by modulating the immune system and reducing the levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17), thereby inhibiting the inflammatory response and potentially slowing radiographic progression in the spine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen Qiangdu Prescription.